Literature DB >> 10593876

Cyclin B-dependent kinase and caspase-1 activation precedes mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis.

R Jorquera1, R M Tanguay.   

Abstract

Hereditary tyrosinemia type I is the most severe metabolic disease of the tyrosine catabolic pathway mainly affecting the liver. It is caused by deficiency of fumarylacetoacetate hydrolase, which prevents degradation of the toxic metabolite fumarylacetoacetate (FAA). We report here that FAA induces common effects (i.e., cell cycle arrest and apoptosis) in both human (HepG2) and rodent (Chinese hamster V79) cells, effects that seem to be temporally related. Both the antiproliferative and apoptosis-inducing activities of FAA are dose dependent and enhanced by glutathione (GSH) depletion with L-buthionine-(S,R)-sulfoximine (BSO). Short treatment (2 h) with 35 microM FAA/+BSO or 100 microM FAA/-BSO induced a transient cell cycle arrest at the G2/M transition (20% and 37%, respectively) 24 h post-treatment. In cells treated with 100 microM FAA/-BSO, an inactivation, followed by a rapid over-induction of cyclin B-dependent kinase occurred, which peaked 24 h post-treatment. Maximum levels of caspase-1 and caspase-3 activation were detected at 3 h and 32 h, respectively, whereas release of mitochondrial cytochrome c was maximal at 24-32 h post-treatment. The G2/M peak declined 24 h later, concomitantly with the appearance of a sub-G1, apoptotic population showing typical nucleosomal-sized DNA fragmentation and reduced mitochondrial transmembrane potential (Deltapsi(m)). These events were prevented by the general caspase inhibitor z-VAD-fmk, whereas G2/M arrest and subsequent apoptosis were abolished by GSH-monoethylester or N-acetylcysteine. Other tyrosine metabolites, maleylacetoacetate and succinylacetone, had no antiproliferative effects and induced only very low levels of apoptosis. These results suggest a modulator role of GSH in FAA-induced cell cycle disturbance and apoptosis where activation of cyclin B-dependent kinase and caspase-1 are early events preceding mitochondrial cytochrome c release, caspase-3 activation, and Deltapsi(m) loss. -Jorquera, R., Tanguay, R. M. Cyclin B-dependent kinase and caspase-1 activation precedes mitochondrial dysfunction in fumarylacetoacetate-induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10593876     DOI: 10.1096/fasebj.13.15.2284

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  13 in total

1.  Hereditary tyrosinemia type 1 from a single center in Egypt: clinical study of 22 cases.

Authors:  Hanaa El-Karaksy; Mona Fahmy; Mona El-Raziky; Nehal El-Koofy; Rokaya El-Sayed; Mohamed S Rashed; Hasan El-Kiki; Ahmad El-Hennawy; Nabil Mohsen
Journal:  World J Pediatr       Date:  2011-06-01       Impact factor: 2.764

2.  Point mutation instability (PIN) mutator phenotype as model for true back mutations seen in hereditary tyrosinemia type 1 - a hypothesis.

Authors:  Etresia van Dyk; Pieter J Pretorius
Journal:  J Inherit Metab Dis       Date:  2011-10-15       Impact factor: 4.982

3.  Sustained phosphorylation of Bid is a marker for resistance to Fas-induced apoptosis during chronic liver diseases.

Authors:  Arndt Vogel; Joseph E Aslan; Holger Willenbring; Christian Klein; Milton Finegold; Howard Mount; Gary Thomas; Markus Grompe
Journal:  Gastroenterology       Date:  2006-01       Impact factor: 22.682

4.  skn-1-Dependent and -independent regulation of aip-1 expression following metabolic stress in Caenorhabditis elegans.

Authors:  Annabel A Ferguson; Mitchell G Springer; Alfred L Fisher
Journal:  Mol Cell Biol       Date:  2010-03-29       Impact factor: 4.272

5.  Multiple correcting COL17A1 mutations in patients with revertant mosaicism of epidermolysis bullosa.

Authors:  Anna M G Pasmooij; Hendri H Pas; Franciska C L Deviaene; Miranda Nijenhuis; Marcel F Jonkman
Journal:  Am J Hum Genet       Date:  2005-09-09       Impact factor: 11.025

6.  Hepatocellular carcinoma despite long-term survival in chronic tyrosinaemia I.

Authors:  S Z Kim; K G Kupke; L Ierardi-Curto; E Holme; J Greter; R M Tanguay; J Poudrier; M D'Astous; F Lettre; S H Hahn; H L Levy
Journal:  J Inherit Metab Dis       Date:  2000-12       Impact factor: 4.982

7.  Nitisinone in the treatment of hereditary tyrosinaemia type 1.

Authors:  Patrick J McKiernan
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 8.  Altered metabolite levels in cancer: implications for tumour biology and cancer therapy.

Authors:  Lucas B Sullivan; Dan Y Gui; Matthew G Vander Heiden
Journal:  Nat Rev Cancer       Date:  2016-09-23       Impact factor: 60.716

9.  The Caenorhabditis elegans K10C2.4 gene encodes a member of the fumarylacetoacetate hydrolase family: a Caenorhabditis elegans model of type I tyrosinemia.

Authors:  Alfred L Fisher; Kathryn E Page; Gordon J Lithgow; Lindsey Nash
Journal:  J Biol Chem       Date:  2008-01-28       Impact factor: 5.157

10.  A universal system to select gene-modified hepatocytes in vivo.

Authors:  Sean Nygaard; Adi Barzel; Annelise Haft; Angela Major; Milton Finegold; Mark A Kay; Markus Grompe
Journal:  Sci Transl Med       Date:  2016-06-08       Impact factor: 17.956

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.